IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Stock Market News for Aug 31, 2021
by Zacks Equity Research
The S&P 500 and the Nasdaq closed at record highs on Monday as investors flocked to technology and consumer discretionary shares, after the Federal Reserve¿¿¿s dovish stance on tapering its monetary stimulus last week.
Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPME
Idexx (IDXX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.
Reasons to Hold on to Veeva Systems (VEEV) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for TIBSOVO
by Zacks Equity Research
Thermo Fisher (TMO) receives FDA go-ahead for the Oncomine Dx Target Test as a CDx for Servier's ivosidenib tablets, TIBSOVO.
SmileDirectClub (SDC) Reels Under Rising Costs, Debt Woes
by Zacks Equity Research
SmileDirectClub (SDC) sees net operating cash outflow in the second quarter.
BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA
by Zacks Equity Research
EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
Here's Why You Should Invest In Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 technology and international expansion of the Control-IQ technology add to the company's solid second-quarter performance.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.
Here's Why You Should Retain PacBio (PACB) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about PacBio (PACB) owing to its slew of strategic deals and strength in its Sequel system.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and raised 2021 outlook.
Petco (WOOF) Q2 Earnings Beat on Continued Demand for Pet Care
by Zacks Equity Research
Petco (WOOF) Q2 earnings exceed estimates on buoyant demand for pet care products and services.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.
Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag
by Zacks Equity Research
Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.
West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about West Pharmaceutical's (WST) robust proprietary products segment and its continued strength in R&D.
Masimo (MASI) Bridge Hailed as Opioid Substitute in New Study
by Zacks Equity Research
Masimo's (MASI) Bridge device is likely to allow more patients to be benefited by auriculotherapy, thereby reducing the possibility of opioid overuse.
ResMed (RMD) Hits New 52-Week High: What's Behind the Rally?
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.
Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes
by Zacks Equity Research
Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.
Globus Medical (GMED) Gets FDA Nod for Excelsius3D
by Zacks Equity Research
The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.
Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev
by Zacks Equity Research
Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.
Time to Focus on IDEXX Laboratories (IDXX) for Strong Earnings Growth Potential
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX Laboratories (IDXX).
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.